HC Wainwright Reaffirms “Buy” Rating for Unicycive Therapeutics (NASDAQ:UNCY)

Unicycive Therapeutics (NASDAQ:UNCY)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a note issued to investors on Wednesday,Benzinga reports. They currently have a $4.00 price target on the stock.

Separately, Benchmark reissued a “speculative buy” rating and set a $3.00 price target on shares of Unicycive Therapeutics in a research report on Friday, November 22nd. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Unicycive Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $5.50.

Unicycive Therapeutics Stock Performance

NASDAQ:UNCY opened at $0.58 on Wednesday. Unicycive Therapeutics has a 52 week low of $0.20 and a 52 week high of $1.82. The firm’s 50-day simple moving average is $0.69 and its 200 day simple moving average is $0.51. The firm has a market cap of $60.20 million, a price-to-earnings ratio of -0.60 and a beta of 2.30.

Institutional Trading of Unicycive Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. XTX Topco Ltd acquired a new position in Unicycive Therapeutics during the third quarter worth about $29,000. Virtu Financial LLC increased its position in Unicycive Therapeutics by 566.8% during the 3rd quarter. Virtu Financial LLC now owns 73,975 shares of the company’s stock worth $30,000 after purchasing an additional 62,881 shares in the last quarter. Bleakley Financial Group LLC bought a new position in Unicycive Therapeutics in the 3rd quarter valued at approximately $33,000. Acuta Capital Partners LLC acquired a new stake in Unicycive Therapeutics in the third quarter valued at approximately $807,000. Finally, Walleye Capital LLC bought a new stake in shares of Unicycive Therapeutics during the third quarter worth $2,040,000. 40.42% of the stock is currently owned by institutional investors.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.